Navitoclax (ABT-263): The Potent Senolytic With Platelet Risk

Expert Summary

Navitoclax (ABT-263) inhibits BCL-2, BCL-XL, and BCL-W simultaneously — covering all the primary anti-apoptotic proteins in senescent cells. In aged mice, navitoclax reduces senescent cell burden by 50–80%, extends healthspan, and improves physical function. Its clinical use for aging is limited by thrombocytopenia: BCL-XL is essential for platelet survival, and navitoclax depletes platelets within hours of dosing.

Key Facts

Frequently Asked Questions

Will navitoclax ever be usable for aging?

Modified navitoclax variants with reduced BCL-XL (platelet-sparing) activity are in development. If successfully engineered, a navitoclax variant could be the most effective aging senolytic ever created. This remains a research frontier.

Why is navitoclax used in cancer treatment if it's dangerous?

In cancer (CLL, small cell lung cancer), the tumor-killing benefit outweighs the thrombocytopenia risk. Patients are monitored closely with platelet transfusions available. For aging patients without cancer, this risk-benefit calculation is unfavorable.

Scientific References

Practical interpretation

Navitoclax is an investigational oncology drug, not a consumer supplement. Its platelet-related toxicity is a major reason it is not suitable for self-experimentation. This page is informational: do not seek or use research chemicals. Any exposure or questions about a prescribed cancer medicine belong with an oncology team.

Senescence research distinguishes cell and animal mechanisms from demonstrated human health outcomes. A change in a marker does not prove that senescent cells were cleared or that symptoms, disease risk, or lifespan changed. No self-directed preventive dose or schedule is established. Do not use prescription drugs or high-dose supplements as an online protocol; discuss relevant symptoms and treatments with a clinician.

Get the free Longevity Supplement Starter Guide

Sign up for the guide and occasional Stacking Years updates. The guide is available on the confirmation screen.